510(k) device
QIAstat-Dx Respiratory Panel Plus
QIAGEN GmbH · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision May 10, 2024, newest Aug 27, 2025COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
3
Naming "QIAstat-Dx"
MAUDE reports
43
Brand "QIAstat-Dx", since 2015
PubMed studies
81
Mentioning "QIAstat-Dx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing QIAstat-Dx Respiratory Panel Plus
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K250080 · Decided Aug 27, 2025 · 226 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "QIAstat-Dx", any status and sponsor, newest update first.
QIAGEN Gaithersburg, IncNot on our public-company list
NCT05305534 · 2,142 participants · Start Dec 1, 2023 · Primary completion Apr 10, 2025
Device: QIAstat-Dx® BCID GN and GPF Plus AMR Panels · For: Blood Disease
Sites: Manchester, United Kingdom
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "QIAstat-Dx", and for the whole product code for context.
This brand
43 reports: 15 malfunction, 28 injury, 0 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
- QIASTAT-DX RESPIRATORY SARS-COV-2 PANELMalfunction
3004013603-2024-00005 · Received Dec 27, 2024 · Event dated Nov 15, 2024
Device type: Reagents, 2019-Novel Coronavirus Nucleic Acid (QJR)
Device problem as coded: No Apparent Adverse Event
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Brand Name: QIAstat-Dx Product Name: QIAstat-Dx Respiratory Panel Plus Reference Number (REF): 691224 Software Version: n/a Component: n/aOpen, Classified
Z-1504-2025 · Started Mar 12, 2025 · Posted by FDA Mar 31, 2025
Reason given: Identified faulty cartridges. If such a faulty cartridge is used for sample testing, false test results could occur.
Cause as FDA categorized it: Mixed-up of materials/components · Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Published research
The most relevant PubMed records for "QIAstat-Dx"[tiab]. The summary above synthesizes these.
- Molecular diagnostics using the QIAstat-Dx syndromic device for covering avian influenza pandemic preparedness.
Peñarrubia L, Reister S, Jiménez-Guzmán S, et al. · Heliyon · 2024
- QIAstat-Dx gastrointestinal panel and Luminex xTAG gastrointestinal pathogen panel comparative evaluation.
Giffen SR, Sadler JM, Miller MB · J Clin Microbiol · 2023
- Performance of the QIAstat-Dx Gastrointestinal Panel for Diagnosing Infectious Gastroenteritis.
Boers SA, Peters CJA, Wessels E, et al. · J Clin Microbiol · 2020
- Comparison of QIAstat-Dx and BioFire FilmArray Gastrointestinal Panels in a Pediatric Population.
Suleiman M, Iqbal M, Tang P, et al. · Microorganisms · 2024
- Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2.
Cassidy H, van Genne M, Lizarazo-Forero E, et al. · Front Microbiol · 2022
- Evaluation of the QIAstat-Dx Meningitis/Encephalitis Panel, a multiplex PCR platform for the detection of community-acquired meningoencephalitis.
Sundelin T, Bialas J, de Diego J, et al. · J Clin Microbiol · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel.
Lebourgeois S, Storto A, Gout B, et al. · Int J Infect Dis · 2021Observational Study
- Multicenter Evaluation of QIAstat-Dx Respiratory Panel V2 for Detection of Viral and Bacterial Respiratory Pathogens.
Boers SA, Melchers WJG, Peters CJA, et al. · J Clin Microbiol · 2020Multicenter Study
- Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel for detection of pathogens in nasopharyngeal and lower respiratory tract specimens.
Caza M, Hayman J, Jassem A, et al. · Diagn Microbiol Infect Dis · 2024Evaluation Study
- Multicenter evaluation of the QIAstat-Dx Gastrointestinal Panel 2, a multiplex PCR platform for the diagnosis of acute gastroenteritis.
Szymczak WA, Engsbro AL, Lisby JG, et al. · J Clin Microbiol · 2025Clinical Study, Multicenter Study
- Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 panel, a rapid multiplex PCR method for the diagnosis of COVID-19.
Ishikane M, Unoki-Kubota H, Moriya A, et al. · J Infect Chemother · 2022
- Evaluation of the QIAstat-Dx BCID GN and GPF kits for direct identification and antimicrobial resistance prediction from blood culture bottles.
Ng S, Tan CY, Yah JY, et al. · J Clin Microbiol · 2024Evaluation Study
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.